Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Income from Continuing Operations (2016 - 2025)

CytomX Therapeutics' Income from Continuing Operations history spans 12 years, with the latest figure at 26510000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 240.44% year-over-year to 26510000.0; the TTM value through Dec 2025 reached 17368000.0, down 154.5%, while the annual FY2025 figure was 17368000.0, 154.5% down from the prior year.
  • Income from Continuing Operations reached 26510000.0 in Q4 2025 per CTMX's latest filing, down from 14229000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 23525000.0 in Q1 2025 to a low of 34823000.0 in Q4 2021.
  • Average Income from Continuing Operations over 5 years is 10062650.0, with a median of 7654500.0 recorded in 2022.
  • The largest YoY upside for Income from Continuing Operations was 2155.2% in 2024 against a maximum downside of 501.1% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 34823000.0 in 2021, then skyrocketed by 74.8% to 8775000.0 in 2022, then surged by 109.54% to 837000.0 in 2023, then soared by 2155.2% to 18876000.0 in 2024, then plummeted by 240.44% to 26510000.0 in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Income from Continuing Operations are 26510000.0 (Q4 2025), 14229000.0 (Q3 2025), and 154000.0 (Q2 2025).